Anti-inflammatory actions of quinapril

Cardiovascular Drugs and Therapy

Volumn 21, Issue 3, 2007, Pages 211-220

  Egido, Jesus ^a   Ruiz Ortega, Marta ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Accupril; Arthritis; Atherosclerosis; C reactive protein; Inflammation; Metabolic syndrome; Renal disease; Scleroderma

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN II; ATENOLOL; ATORVASTATIN; BOSENTAN; C REACTIVE PROTEIN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DOXAZOSIN; ENALAPRIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRBESARTAN; LOSARTAN; PERINDOPRIL; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL;

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ATHEROSCLEROSIS; CHEMOTAXIS; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DIABETES MELLITUS; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATORY CELL; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; NEPHRITIS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; REVIEW; SCLERODERMA; SIGNAL TRANSDUCTION;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; TETRAHYDROISOQUINOLINES;

EID: 34249280963     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-007-6019-1     Document Type: Review

References (87)

1. Becker RH, Wiemer G, Linz W. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol 1991;18:S110-5.
2. Bell JP, Mosfer SI, Lang D, Donaldson F, Lewis MJ. Vitamin C and quinapril abrogate LVH and endothelial dysfunction in aortic-banded guinea pigs. Am J Physiol Heart Circ Physiol 2001;281:H1704-10.
3. Blanco S, Vaquero M, Gomez-Guerrero C, López D, Egido J, Romero R, et al. Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension. Am J Hypertens 2005;18:557-65.
4. Candido R, Jandeleit-Dahm KA, Cao Z, Nesteroff SP, Burns WC, Twigg SM, et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002;106:246-53.
5. Carey RM, Siragy HM. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab 2003;14:274-81.
6. Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 1998;83:952-9.
7. Cheng ZJ, Vaskonen T, Tikkanen I, Nurminen K, Ruskaoho H, Vapaatalo H, et al. Endothelial dysfunction and salt sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats. Hypertension 2001;37:433-9.
8. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
9. Dalbeth N, Edwards J, Callan MFC, Hall FC. The angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis (Abstract OP50). Rheumatology (Oxford) 2004;43:ii20.
10. Dalbeth N, Edwards J, Fairchild S, Callan M, Hall FC. The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis. Rheumatology (Oxford) 2005;44:24-31.
11. Dandona P, Kumar V, Aljada A, Ghanim H, Syed T, Hofmayer D, et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab 2003;88:4496-501.
12. Dzau VJ. Theodore Cooper lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001;37:1047-52.
13. Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlof B, Deanfield J, et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther 2002;16:149-60.
14. Esteban V, Lorenzo O, Ruperez M, Suzuki Y, Mezzano S, Blanco J, et al. Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol 2004;15:1514-29.
15. Fabris B, Chen BZ, Pupic V, Perich R, Johnston CI. Inhibition of angiotensin-converting enzyme (ACE) in plasma and tissue. J Cardiovasc Pharmacol 1990a;15:S6-13.
16. Fabris B, Jackson B, Kohzuki M, Perich R, Johnston CI. Increased cardiac angiotensin-converting enzyme in rats with chronic heart failure. Clin Exp Pharmacol Physiol 1990b;17:309-14.
17. Fukuzawa M, Satoh J, Sagara M, Muto G, Muto Y, Nishimura S, et al. Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo. Immunopharmacology 1997;36:49-55.
18. Gallego-Delgado J, Lazaro A, Gomez-Garre D, Osende JI, Gonzelez-Rubio ML, Herraiz M, et al. Long term organ protection by doxazosin and/or quinapril in long-term antihypertensive therapy. J Nephrol 2006a;19:588-98.
19. Gallego-Delgado J, Lazaro A, Osende JI, Barderas MG, Duran MC, Vivanco F, et al. Comparison of the protein profile of established and regressed hypertension-induced left ventricular hypertrophy. J Proteome Res 2006b;5:404-13.
20. Goto M, Fujisawa M, Yamada A, Okabe T, Takaku F, Sasano M, et al. Spontaneous release of angiotensin converting enzyme and interleukin 1 beta from peripheral blood monocytes from patients with rheumatoid arthritis under a serum free condition. Ann Rheum Dis 1990;49:172-6.
21. Goto M, Sasano M, Fuzisawa M, Okabe T, Nishizawa K. Constitutive production of angiotensin converting enzyme from rheumatoid nodule cells under serum free conditions. Ann Rheum Dis 1992;51:741-2.
22. Guba M, Steinbauer M, Buchner M, Frolich D, Farkas S, Jauch KW, et al. Differential effects of short-term ace- and AT1-receptor inhibition on postischemic injury and leukocyte adherence in vivo and in vitro. Shock 2000;13:190-6.
23. Guijarro C, Egido J. Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney Int 2001;59:415-24.
24. Han Y, Runge MS, Brasier AR. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res 1999;84:695-703.
25. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
26. Hernandez-Presa M, Bustos C, Ortego M, Tuñon J, Renedo G, Ruiz-Ortega M, et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997;95:1532-41.
27. Hernandez-Presa MA, Bustos C, Ortego M, Tuñon J, Ortega L, Egido J. ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. Am J Pathol 1998;153:1825-37.
28. Hisada Y, Sugaya T, Tanaka S, Suzuki Y, Ra C, Kimura K, et al. An essential role of angiotensin II receptor type-1 in recipient kidney, not in transplanted peripheral blood leukocytes, in progressive immune-mediated renal injury. Lab Invest 2001;81:1243-51.
29. Hornig B, Arakawa N, Haussmann D, Drexler H. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998;98:2842-8.
30. Jackson EK. Renin and angiotensin. In: Brunton L, Lazo J, Parker K, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2006. pp. 789-822.
31. Johnston CI, Fabris B, Yamada H, Mendelsohn FA, Cubela R, Sivell D, et al. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens Suppl 1989;7:S11-6.
32. Juan W, Nakazawa M, Watanabe K, Ma M, Wahed MI, Hasegawa G, et al. Quinapril inhibits progression of heart failure and fibrosis in rats with dilated cardiomyopathy after myocarditis. Mol Cell Biochem 2003;251:77-82.
33. Khan BV, Sola S, Lauten WB, Natarajan R, Hooper WC, Menon RG, et al. Quinapril, an ACE inhibitor, reduces markers of oxidative stress in the metabolic syndrome. Diabetes Care 2004;27:1712-5.
34. Kiarash A, Pagano PJ, Tayeh M, Rhaleb NE, Carretero OA. Upregulated expression of rat heart intercellular adhesion molecule-1 in angiotensin II- but not phenylephrine- induced hypertension. Hypertension 2001;37:58-65.
35. Klahr S, Morrissey JJ. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Inter Suppl 2000;75:S7-14.
36. Kranzhofer R, Browatzki M, Schmidt J, Kubler W. Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochem Biophys Res Commun 1999;257:826-8.
37. Largo R, Gomez-Garre D, Liu XH, Alonso J, Blanco J, Plaza JJ, et al. Endothelin-1 upregulation in the kidney of uninephrectomized spontaneously hypertensive rats and its modification by the angiotensin-converting enzyme inhibitor quinapril. Hypertension 1997;29:1178-85.
38. Lauten WB, Khan QA, Rajagopalan S, Lerakis S, Rahman ST, Parthasarathy S, et al. Usefulness of quinapril and irbesartan to improve the anti-inflammatory response of atorvastatin and aspirin in patients with coronary heart disease. Am J Cardiol 2003;91:1116-9.
39. Lazaro A, Gallego-Delgado J, Justo P, Estaban V, Osende J, Mezzano S, et al. Long-term blood pressure control prevents oxidative renal injury. Antioxid Redox Signal 2005;7:1285-93.
40. Lin AT, Clements PJ, Furst DE. Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosis. Rheum Dis Clin North Am 2003;29:409-26.
41. Lopez-Jaramillo P, Casas JP. Blockade of endothelial enzymes: new therapeutic targets. J Hum Hypertens 2002;16:S100-3.
42. Lopez Santi RG, Valeff EC, Duymovich CR, Mazzoitta D, Mijailovsky NE, Filippa GC, et al. Effects of an angiotensin-converting enzyme inhibitor (ramipril) on inflammatory markers in secondary prevention patients: RAICES study. Coron Artery Dis 2005;16:423-9.
43. Lorenzo O, Ruiz-Ortega M, Esbrit P, Ruperez M, Ortega A, Santos S, et al. Angiotensin II increases parathyroid hormone-related protein (PTHrP) and the type 1 PTH/PTHrP receptor in the kidney. J Am Soc Nephrol 2002a;13:1595-607.
44. Lorenzo O, Ruiz-Ortega M, Suzuki Y, Ruperez M, Esteban V, Sugaya T, et al. Angiotensin III activates nuclear transcription factor-kappaB in cultured mesangial cells mainly via AT(2) receptors: studies with AT(1) receptor-knockout mice. J Am Soc Nephrol 2002b;13:1162-71.
45. Maddison P. Prevention of vascular damage in scleroderma with angiotensin-converting enzyme (ACE) inhibition. Rheumatology (Oxford) 2002;41:965-71.
46. Mann DL. Angiotensin II as an inflammatory mediator: evolving concepts in the role of the renin angiotensin system in the failing heart. Cardiovasc Drugs Ther 2002;16:7-9.
47. Marok R, Winyard PG, Coumbe A, Kus ML, Gaffney K, Blades S, et al. Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum 1996;39:583-91.
48. Mezzano S, Aros C, Droguett A, Burgos ME, Ardiles L, Flores C, et al. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 2004;19:2505-12.
49. Morrissey JJ, Klahr S. Differential effects of ACE and AT1 receptor inhibition on chemoattractant and adhesion molecule synthesis. Am J Physiol 1998;274:F580-6.
50. Muller DN, Dechend R, Mervaala EM, Park J-K, Schmidt F, Fiebeler A, et al. NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 2000;35:193-201.
51. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292:2343-9.
52. Oosterga M, Voors AA, Buikema H, Pinto YM, Haber HE, Ebels T, et al. Angiotensin II formation in human vasculature after chronic ACE inhibition: a prospective, randomized, placebo-controlled study. QUO VADIS investigators. Cardiovasc Drugs Ther 2000;14:55-60.
53. Oosterga M, Voors AA, Pinto YM, Buikema H, Grandjean JG, Kingma JH, et al. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril on vascular ace and determinants of ischemia. Am J Cardiol 2001;87:542-6.
54. Ortega A, Ramila D, Izquierdo A, Gonzalez L, Barat A, Gazapo R, et al. Role of the renin-angiotensin system on the parathyroid hormone-related protein overexpression induced by nephrotoxic acute renal failure in the rat. J Am Soc Nephrol 2005;16:939-49.
55. Oubina MP, de las Heras N, Cediel E, Sanz-Rosa D, Aragoncillo P, Diaz C, et al. Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibition on inflammatory markers in atherosclerotic rabbits. Clin Sci (Lond) 2003;105:655-62.
56. Park JK, Pagano PJ, Tayeh M, Rhaleb NE, Carretero OA. Lacidipine inhibits adhesion molecule and oxidase expression independent of blood pressure reduction in angiotensin-induced vascular injury. Hypertension 2002;39:685-9.
57. Pastore L, Tessitore A, Martinotti S, Toniato E, Alesse E, Bravi MC, et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 1999;100:1646-52.
58. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000;20:645-51.
59. Ricardo SD, Levinson ME, DeJoseph MR, Diamond JR. Expression of adhesion molecules in rat renal cortex during experimental hydronephrosis. Kidney Int 1996;50:2002-10.
60. Ruiz-Ortega M, Bustos C, Hernandez-Presa MA, Lorenzo O, Plaza JJ, Egido J. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 1998;161:430-9.
61. Ruiz-Ortega M, Gomez-Garre D, Liu XH, Blanco J, Largo R, Egido J. Quinapril decreases renal endothelin-1 expression and synthesis in a normotensive model of immune-complex nephritis. J Am Soc Nephrol 1997;8:756-68.
62. Ruiz-Ortega M, Gonzalez S, Seron D, Condom E, Bustos C, Largo R, et al. ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Kidney Int 1995;48:1778-91.
63. Ruiz-Ortega M, Lorenzo O, Ruperez M, König S, Wittig B, Egido J. Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. Circ Res 2000;86:1266-72.
64. Ruiz-Ortega M, Lorenzo O, Ruperez M, Blanco J, Egido J. Systemic infusion of angiotensin II into normal rats activates nuclear factor-kappaB and AP-1 in the kidney: role of AT(1) and AT(2) receptors. Am J Pathol 2001a;158:1743-56.
65. Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Suzuki Y, Mezzano S, et al. Role of the renin-angiotensin system in vascular diseases: expanding the field. Hypertension 2001b;38:1382-7.
66. Ruiz-Ortega M, Lorenzo O, Ruperez M, Suzuki Y, Egido J. Angiotensin II activates nuclear transcription factor-kB in aorta of normal rats and in vascular smooth muscle of AT-1 knockout mice. Nephrol Dial Transplant 2001c;16:1-7.
67. Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, et al. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Inter Suppl 2002:12-22.
68. Ruperez M, Ruiz-Ortega M, Esteban V, Lorenzo O, Mezzano S, Plaza JJ, et al. Angiotensin II increases connective tissue growth factor in the kidney. Am J Pathol 2003;163:1937-47.
69. Sanz M, Ganado P, Ruiz E, Tejerina T. Effect of trandolapril on vascular responsiveness in cholesterol-fed rabbit-isolated arteries. Eur J Pharmacol 2000;397:359-65.
70. Singh K, Sirokman G, Communal C, Robinson KG, Conrad CH, Brooks WW, et al. Myocardial osteopontin expression coincides with the development of heart failure. Hypertension 1999;33:663-70.
71. Soto K, Gomez-Garre D, Largo R, Gallego-Delgado J, Tejera N, Catalina MP, et al. Tight blood pressure control decreases apoptosis during renal damage. Kidney Int 2004;65:811-22.
72. Suzuki Y, Lopez-Franco O, Gomez-Garre D, Tejera N, Gomez-Guerrero C, Sugaya T, et al. Renal tubulointerstitial damage caused by persistent proteinuria is attenuated in AT1-deficient mice: role of endothelin-1. Am J Pathol 2001;159:1895-904.
73. Takemori K, Ito H, Suzuki T. Effects of the AT1 receptor antagonist on adhesion molecule expression in leukocytes and brain microvessels of stroke-prone spontaneously hypertensive rats. Am J Hypertens 2000;13:1233-41.
74. Tojo A, Onozato ML, Kobayashi N, Goto A, Matsuoka H, Fujita T, et al. Angiotensin II and oxidative stress in Dahl Salt-sensitive rat with heart failure. Hypertension 2002;40:834-9.
75. Touyz RM. Recent advances in intracellular signalling in hypertension. Curr Opin Nephrol Hypertens 2003;12:165-74.
76. Tsikouris JP, Suarez JA, Simoni JS, Ziska M, Meyerrose GE. Exploring the effects of ACE inhibitor tissue penetration on vascular inflammation following acute myocardial infarction. Coron Artery Dis 2004;15:211-7.
77. Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes CP, Alexander RW, et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis. Circulation 1999;100:1223-9.
78. van Haelst PL, Tervaert JW, van Geel PP, Veeger NJ, Gurne O, Gans RO, et al. Long term angiotensin converting enzyme-inhibition in patients after coronary artery bypass grafting reduces levels of soluble intercellular cell adhesion molecule-1. Eur J Vasc Endovasc Surg 2003;26:387-91.
79. Veale D, Yanni G, Bresnihan B, FitzGerald O. Production of angiotensin converting enzyme by rheumatoid synovial membrane. Ann Rheum Dis 1992;51:476-80.
80. Walsh DA, Catravas J, Wharton J. Angiotensin converting enzyme in human synovium: increased stromal [(125)I]351A binding in rheumatoid arthritis. Ann Rheum Dis 2000;59:125-31.
81. We GC, Siroi MG, Qu R, Liu P, Roulea JL. Effects of quinapril on myocardial function, ventricular remodeling and cardiac cytokine expression in congestive heart failure in the rat. Cardiovasc Drugs Ther 2002;16:29-36.
82. Wolf G, Schneider A, Helmchen U, Stahl RA. AT1-receptor antagonists abolish glomerular MCP-1 expression in a model of mesangial proliferative glomerulonephritis. Exp Nephrol 1998;6:112-20.
83. Wolf G, Wenzel U, Burns KD, Harris RC, Stahl RA, Thaiss F. Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors. Kidney Int 2002;61:1986-95.
84. Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F. Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int 2001;60:1645-57.
85. Yang L, Gao YJ, Lee RM. The effects of quinapril and atorvastatin on artery structure and function in adult spontaneously hypertensive rats. Eur J Pharmacol 2005;518:145-51.
86. Yu XQ, Wu LL, Huang XR, Yang N, Gilbert RE, Cooper ME, et al. Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II. Kidney Int 2000;58:1469-80.
87. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 2000;342:145-53.